JP2014509656A - 炎症および免疫の治療 - Google Patents

炎症および免疫の治療 Download PDF

Info

Publication number
JP2014509656A
JP2014509656A JP2014502855A JP2014502855A JP2014509656A JP 2014509656 A JP2014509656 A JP 2014509656A JP 2014502855 A JP2014502855 A JP 2014502855A JP 2014502855 A JP2014502855 A JP 2014502855A JP 2014509656 A JP2014509656 A JP 2014509656A
Authority
JP
Japan
Prior art keywords
subject
composition
proanthocyanidins
weight
colitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014502855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509656A5 (enExample
Inventor
クリスティーナ クー
ディアン リスカ
スーザン エス． パーシバル
Original Assignee
オーシャン スプレー クランベリーズ インコーポレイテッド
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーシャン スプレー クランベリーズ インコーポレイテッド, ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド filed Critical オーシャン スプレー クランベリーズ インコーポレイテッド
Publication of JP2014509656A publication Critical patent/JP2014509656A/ja
Publication of JP2014509656A5 publication Critical patent/JP2014509656A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014502855A 2011-04-01 2012-03-30 炎症および免疫の治療 Pending JP2014509656A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161471073P 2011-04-01 2011-04-01
US61/471,073 2011-04-01
PCT/US2012/031581 WO2012135702A1 (en) 2011-04-01 2012-03-30 Inflammation and immunity treatments

Publications (2)

Publication Number Publication Date
JP2014509656A true JP2014509656A (ja) 2014-04-21
JP2014509656A5 JP2014509656A5 (enExample) 2015-04-23

Family

ID=46931951

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014502855A Pending JP2014509656A (ja) 2011-04-01 2012-03-30 炎症および免疫の治療

Country Status (4)

Country Link
US (1) US9895341B2 (enExample)
JP (1) JP2014509656A (enExample)
CA (1) CA2832059C (enExample)
WO (1) WO2012135702A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20130476A1 (it) * 2013-03-28 2014-09-29 Novintethical Pharma Sagl Composizioni per il trattamento di disturbi gastro-intestinali a base di complessi di tannini con proteine
US10034704B2 (en) 2015-06-30 2018-07-31 Ethicon Llc Surgical instrument with user adaptable algorithms
JOP20190276A1 (ar) * 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2975997B2 (ja) * 1998-03-04 1999-11-10 工業技術院長 プロアントシアニジンａおよびその誘導体
JP2001524938A (ja) * 1996-10-16 2001-12-04 シャーマン ファーマシューティカルズ，インコーポレーテッド プロアントシアニジンポリマー止瀉組成物の腸溶製剤
WO2005030200A1 (ja) * 2003-09-26 2005-04-07 Kirin Beer Kabushiki Kaisha 自己免疫疾患治療剤
JP2007077122A (ja) * 2005-09-16 2007-03-29 Asahi Breweries Ltd 炎症性腸疾患予防剤
JP2007518812A (ja) * 2004-01-23 2007-07-12 フェノーリックス、エルエルシー フェノール化合物に富む組成物及びその製造方法
WO2008004224A2 (en) * 2006-07-03 2008-01-10 Arie Levine Synergistic compositions for crohn's disease and inflammatory gastrointestinal disorders
JP2009535417A (ja) * 2006-05-01 2009-10-01 ナポ ファーマシューティカルズ インク． 下痢型過敏性腸症候群の治療方法
JP2010168300A (ja) * 2009-01-21 2010-08-05 Efuekuto:Kk プロアントシアニジン三量体
WO2010121203A1 (en) * 2009-04-16 2010-10-21 Ocean Spray Cranberries, Inc. Phenolics extraction and use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020054924A1 (en) * 2000-04-13 2002-05-09 Leahy Margaret M. Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor
US20090226548A1 (en) * 2008-01-11 2009-09-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using a synergistic cranberry derivative and d-mannose composition
WO2011088420A1 (en) * 2010-01-15 2011-07-21 Ocean Spray Cranberries, Inc. Process for extracting compound from cranberry leaves and related products
US9314494B2 (en) * 2012-05-25 2016-04-19 The United States Of America, As Represented By The Secretary Of Agriculture Cranberry xyloglucan oligosaccharide composition

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001524938A (ja) * 1996-10-16 2001-12-04 シャーマン ファーマシューティカルズ，インコーポレーテッド プロアントシアニジンポリマー止瀉組成物の腸溶製剤
JP2975997B2 (ja) * 1998-03-04 1999-11-10 工業技術院長 プロアントシアニジンａおよびその誘導体
WO2005030200A1 (ja) * 2003-09-26 2005-04-07 Kirin Beer Kabushiki Kaisha 自己免疫疾患治療剤
JP2007518812A (ja) * 2004-01-23 2007-07-12 フェノーリックス、エルエルシー フェノール化合物に富む組成物及びその製造方法
JP2007077122A (ja) * 2005-09-16 2007-03-29 Asahi Breweries Ltd 炎症性腸疾患予防剤
JP2009535417A (ja) * 2006-05-01 2009-10-01 ナポ ファーマシューティカルズ インク． 下痢型過敏性腸症候群の治療方法
WO2008004224A2 (en) * 2006-07-03 2008-01-10 Arie Levine Synergistic compositions for crohn's disease and inflammatory gastrointestinal disorders
JP2010168300A (ja) * 2009-01-21 2010-08-05 Efuekuto:Kk プロアントシアニジン三量体
WO2010121203A1 (en) * 2009-04-16 2010-10-21 Ocean Spray Cranberries, Inc. Phenolics extraction and use

Also Published As

Publication number Publication date
CA2832059C (en) 2020-07-14
CA2832059A1 (en) 2012-10-04
US9895341B2 (en) 2018-02-20
WO2012135702A1 (en) 2012-10-04
US20140134206A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
Peng et al. Gut microbiota modulation and anti-inflammatory properties of anthocyanins from the fruits of Lycium ruthenicum Murray in dextran sodium sulfate-induced colitis in mice
Tzounis et al. Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study
JP7011885B2 (ja) 腸の健康を促す組成物
Gallotti et al. Effects of dietary fibre intake in chemotherapy-induced mucositis in murine model
CN107206030A (zh) 包含生酸拟杆菌作为有效成分的用于预防或治疗代谢性疾病的药学组合物
Wan et al. Dicaffeoylquinic acids from Ilex kudingcha attenuate dextran sulfate sodium-induced colitis in C57BL/6 mice in association with the modulation of gut microbiota
Ran et al. Preventive effect of Chinese dwarf cherry [Cerasus humilis (Bge.) Sok.] fermentation juice on dextran sulfate sodium-induced ulcerative colitis rats through the regulation of IgA and the intestinal immune barrier
JP2021130717A (ja) ディスバイオシスの治療のために用いられるブドウ果皮
KR20200138333A (ko) 염증성 장 질환을 치료하는 조성물 및 방법
KR20190086382A (ko) 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도
JP2013035858A (ja) 抗炎症用組成物
Zhou et al. Miao sour soup influences serum lipid via regulation of high‐fat diet‐induced intestinal flora in obese rats
US9895341B2 (en) Inflammation and immunity treatments
Wang et al. Vitamin K2 alleviates dextran sulfate sodium-induced colitis via inflammatory responses, gut barrier integrity, and the gut microbiota in mice
Fu et al. Fermented sea buckthorn compound juice inhibits colorectal cancer growth by regulating immunity and the gut microbiome
US12257240B2 (en) Combination of berberine and derivatives thereof, and vitamin B12
CN119699581A (zh) 营养组合物、包含其的食品及该营养组合物的应用
CN102038702A (zh) 一种橙皮苷的抗衰老应用
JP2022522151A (ja) 新規なラクトバチルスサケイｃｖｌ－００１菌株又はその培養液を含む骨疾患又は代謝性疾患改善、予防又は治療用組成物
CN107073032A (zh) 肾衰竭发展抑制剂、肾衰竭预防剂及硫酸吲哚酚产生抑制剂
TWI721549B (zh) 戈氏副擬桿菌用於治療慢性腎臟疾病之用途
CN117898436B (zh) 一种预防帕金森病的组合物及其应用
JP7601332B2 (ja) 便秘解消組成物
Li et al. Resveratrol attenuates Citrobacter rodentium-infected colitis by remodeling the gut microbiota structure and inhibiting CD4+ cell activation in mice
WO2020111239A1 (ja) 抗炎症剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150306

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160412

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160921